SPRI | Chronic Myeloid Leukemia (2016 EN)

Discussion in 'Medicine' started by Kanka, May 30, 2020.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    16,395
    Likes Received:
    485
    Trophy Points:
    83
    [​IMG]

    Author: Rüdiger Hehlmann (Editor)
    Full Title: Chronic Myeloid Leukemia
    Publisher: Springer; 1st ed. 2016 edition (August 19, 2016)
    Year: 2016
    ISBN-13: 9783319331980 (978-3-319-33198-0), 9783319331973 (978-3-319-33197-3), 9783319814513 (978-3-319-81451-3)
    ISBN-10: 3319331981, 3319331973, 3319814516
    Pages: 255
    Language: English
    Genre: Medicine: Internal Medicine
    File type: PDF (True)
    Quality: 10/10
    Price: 124.79 €


    This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.

    -------------